1. Pavia Experience in Reoperative Pulmonary Endarterectomy.
- Author
-
Merli VN, Vistarini N, Grazioli V, Sciortino A, Pin M, Parisi I, and D'Armini AM
- Subjects
- Adolescent, Adult, Aged, Arterial Pressure, Clinical Decision-Making, Endarterectomy adverse effects, Endarterectomy mortality, Female, Hospital Mortality, Humans, Hypertension, Pulmonary diagnosis, Hypertension, Pulmonary mortality, Hypertension, Pulmonary physiopathology, Italy, Male, Middle Aged, Pulmonary Artery physiopathology, Pulmonary Embolism diagnosis, Pulmonary Embolism mortality, Pulmonary Embolism physiopathology, Reoperation, Retrospective Studies, Risk Factors, Time Factors, Treatment Outcome, Vascular Resistance, Young Adult, Endarterectomy methods, Hemodynamics, Hypertension, Pulmonary surgery, Pulmonary Artery surgery, Pulmonary Embolism surgery
- Abstract
In our experience, we reperformed pulmonary endarterectomy (PEA) in 10 patients who previously underwent a first PEA. We analyzed this cohort of patients to investigate the main causes of recurrence of symptomatic pathology and the clinical and hemodynamic results of redo surgery. Between 1994 and April 2016, 10 of 716 patients were reoperated at our institution. Available postoperative data were analyzed, and a comparison between first and second PEA hemodynamic and clinical results was carried out. In-hospital mortality rate was also evaluated. After reoperation, mean pulmonary arterial pressure decreased from 45?±?9 to 34?±?10?mm Hg, and pulmonary vascular resistance reduced from 932?±?346?dyne*s*cm
?5 to 428?±?207?dyne*s*cm?5 . Hemodynamic data revealed worthy results of redo PEA, although they are less important than after first PEA. The World Health Organization (WHO) functional class improvement demonstrated satisfactory clinical results. In-hospital mortality of repeat PEA is 40%. Reoperative PEA operative candidacy should be assessed in case of young patients, no other risk factor, and recent medical history of pulmonary hypertension. In the other cases, in-hospital mortality rate is very high and pulmonary hypertension-specific drug therapy or interventional approach should be previously considered., (Copyright © 2017 Elsevier Inc. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF